Insights

Innovative Pipeline Silence Therapeutics has a robust pipeline of siRNA-based therapeutics targeting genetically-based diseases, with promising topline data from multiple Phase 2 trials, including reductions in Lipoprotein(a) levels, indicating a strong growth opportunity in cardiovascular and hematology markets.

Strategic Collaborations With over 20 years of RNAi experience and a validated mRNAi GOLD™ platform, the company positions itself as a key partner for pharmaceutical companies seeking to incorporate RNA interference technologies into their discovery pipelines, creating potential licensing and partnership opportunities.

Financial Growth Having recently secured $120 million in oversubscribed funding and generating revenue between $25 million and $50 million, Silence Therapeutics demonstrates solid financial strength and capacity to scale operations, making it attractive for investors and partners seeking innovative biotech solutions.

Clinical Leadership Active participation in major industry events like the European Hematology Association and American Heart Association showcases the company's commitment to advancing clinical research, which can open doors for partnerships with research institutions and healthcare providers interested in cutting-edge gene-silencing therapies.

Market Focus Silence's emphasis on liver-targeting technology and treating conditions with limited or inadequate current therapies suggests opportunities for targeted medical sales and collaborations with specialists in genetic, cardiovascular, and hematologic conditions, expanding market reach in these niche areas.

Silence Therapeutics plc Tech Stack

Silence Therapeutics plc uses 8 technology products and services including Veeam, WordPress, Twemoji, and more. Explore Silence Therapeutics plc's tech stack below.

  • Veeam
    Backup And Recovery
  • WordPress
    Content Management System
  • Twemoji
    Font Scripts
  • Indeed
    Human Resource Management System
  • Sage People
    Human Resource Management System
  • X-XSS-Protection
    Security
  • X-Content-Type-Options
    Web & Portal Technology
  • Q4 Cookie Monster
    Widgets

Media & News

Silence Therapeutics plc's Email Address Formats

Silence Therapeutics plc uses at least 1 format(s):
Silence Therapeutics plc Email FormatsExamplePercentage
F.Last@silence-therapeutics.comJ.Doe@silence-therapeutics.com
83%
FLast@silence-therapeutics.comJDoe@silence-therapeutics.com
13%
Last@silence-therapeutics.comDoe@silence-therapeutics.com
3%
First@silence-therapeutics.comJohn@silence-therapeutics.com
1%

Frequently Asked Questions

Where is Silence Therapeutics plc's headquarters located?

Minus sign iconPlus sign icon
Silence Therapeutics plc's main headquarters is located at 72 Hammersmith Road, London, W14 8TH, GB. The company has employees across 2 continents, including EuropeNorth America.

What is Silence Therapeutics plc's phone number?

Minus sign iconPlus sign icon
You can contact Silence Therapeutics plc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Silence Therapeutics plc's stock symbol?

Minus sign iconPlus sign icon
Silence Therapeutics plc is a publicly traded company; the company's stock symbol is SLN.

What is Silence Therapeutics plc's official website and social media links?

Minus sign iconPlus sign icon
Silence Therapeutics plc's official website is silence-therapeutics.com and has social profiles on LinkedInCrunchbase.

What is Silence Therapeutics plc's SIC code NAICS code?

Minus sign iconPlus sign icon
Silence Therapeutics plc's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Silence Therapeutics plc have currently?

Minus sign iconPlus sign icon
As of October 2025, Silence Therapeutics plc has approximately 97 employees across 2 continents, including EuropeNorth America. Key team members include Chief Scientific Officer: M. W. L.Chief Medical Officer, Svp: C. R.Chief Financial Officer: C. T.. Explore Silence Therapeutics plc's employee directory with LeadIQ.

What industry does Silence Therapeutics plc belong to?

Minus sign iconPlus sign icon
Silence Therapeutics plc operates in the Biotechnology Research industry.

What technology does Silence Therapeutics plc use?

Minus sign iconPlus sign icon
Silence Therapeutics plc's tech stack includes VeeamWordPressTwemojiIndeedSage PeopleX-XSS-ProtectionX-Content-Type-OptionsQ4 Cookie Monster.

What is Silence Therapeutics plc's email format?

Minus sign iconPlus sign icon
Silence Therapeutics plc's email format typically follows the pattern of F.Last@silence-therapeutics.com. Find more Silence Therapeutics plc email formats with LeadIQ.

How much funding has Silence Therapeutics plc raised to date?

Minus sign iconPlus sign icon
As of October 2025, Silence Therapeutics plc has raised $120M in funding. The last funding round occurred on Feb 05, 2024 for $120M.

When was Silence Therapeutics plc founded?

Minus sign iconPlus sign icon
Silence Therapeutics plc was founded in 1999.
Silence Therapeutics plc

Silence Therapeutics plc

Biotechnology ResearchUnited Kingdom51-200 Employees

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a 
partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add 
this revolutionary modality to their discovery pipeline. As pioneers in the design and development of 
siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to 
potentially address the needs of patients who have limited or inadequate treatment options.
Our mission is to use our technology to create a new generation of therapeutics which can improve 
outcomes for patients and, in the process, build shareholder value.
We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for 
diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the 
opportunity to address a wide range of conditions in virtually any therapeutic area. 

Silence Therapeutics only accepts job applications through our official careers site at Silence-Therapeutics.com/Careers.  If you’re contacted by someone claiming to represent Silence Therapeutics outside of these channels, please be cautious. Do not share personal or financial information unless you’re applying through our verified platforms.  If you’re unsure about a message or job offer, feel free to contact us at HR@Silence-Therapeutics.com to ensure it’s legitimate.

Section iconCompany Overview

Headquarters
72 Hammersmith Road, London, W14 8TH, GB
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
SLN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1999
Employees
51-200

Section iconFunding & Financials

  • $120M

    Silence Therapeutics plc has raised a total of $120M of funding over 5 rounds. Their latest funding round was raised on Feb 05, 2024 in the amount of $120M.

  • $25M$50M

    Silence Therapeutics plc's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $120M

    Silence Therapeutics plc has raised a total of $120M of funding over 5 rounds. Their latest funding round was raised on Feb 05, 2024 in the amount of $120M.

  • $25M$50M

    Silence Therapeutics plc's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.